| Biomarker ID | 816 |
| PMID | 22117988 |
| Year | 2011 |
| Biomarker | ARHI |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Downregulated in aggressive Prostate Cancer (Aggressive:9.6 ± 1.2; Non Agressive: 8.3 ± 2.3 ) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Agressive Vs Non - Agressive Prostate Cancer |
| Type of Biomarker | Prognostic |
| Cohort | Tumour tissues from patients with non-aggressive (n = 18) or aggressive (n = 17) prostate cancer were taken for study. tumours of Gleason grade < 7 were designated as non-aggressive and those of Gleason grade ≥ 7 were designated as aggressive. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.001 |
| Method Used | real-time reverse transcription–polymerase chain reaction (RT-PCR) |
| Clinical | No |
| Remarks | Expression of the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control. ARHI mRNA levels relative to expression of the housekeeping gene: GAPDH) |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | ARHI |